Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity

 

Key Data:

Drug (Brand/Generic)
Acomplia / rimonabant
Company/Licensee
Sanofi-Aventis
Therapy Class
Cannabinoid receptor antagonist
Product Description
Selective inhibitor of the CB1 endocannabinoid receptor
Current Indication
Treatment of obesity in combination with dietary control
Market Sector
Nutrition
Development Status
Withdrawn Europe; NDA withdrawn in US



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development